{"entity":{"id":"nct05112991","kind":"trial","name":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer","aka":[],"tldr":"A phase 2 trial of Envafolimab, Lenvatinib in endometrial cancer, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.","summary":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer is a phase 2 interventional study registered as NCT05112991 by 3D Medicines (Sichuan) Co., Ltd., with 108 participants planned, started 2022-03-04 and due to reach its primary completion in 2026-12. Interventions recorded: Envafolimab+Lenvatinib, Envafolimab. Conditions listed: Advanced Endometrial Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05112991","url":"https://clinicaltrials.gov/study/NCT05112991"}],"tags":["ctgov-ingest"],"related":[],"cancers":["endometrial","advanced-recurrent-endometrial-cancer"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","kinase-inhibitors","monoclonal-antibody"],"targets":[],"drugs":["envafolimab","lenvatinib"],"companies":["3d-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05112991","phase":"2","setting":"An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer","sponsor":"3D Medicines (Sichuan) Co., Ltd.","started":"2022-03-04","startedType":"actual","enrolled":108,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05112991/","neighbours":{"cancer":[{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/"},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"}],"company":[{"id":"3d-medicines","kind":"company","name":"3D Medicines","route":"/companies/3d-medicines/"}]}}